Document Detail


Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial.
MedLine Citation:
PMID:  2196355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine whether prenatal corticosteroid therapy would reduce the incidence of neonatal necrotizing enterocolitis (NEC), we assigned a total of 466 women admitted in premature labor either to receive placebo (group A, n = 256), if delivery was expected to occur within 24 hours of admission, or to receive betamethasone (group B, n = 210) if delivery was expected to take place more than 24 hours after admission. All women were free of severe medical complications or drug therapy; cases of intrauterine growth retardation or premature rupture of the membranes were excluded. Their newborn infants, excluding malformed, congenitally infected, and growth-retarded infants, were enrolled in the study unless they had died before the age of 10 postnatal days. Babies born to group A mothers (n = 248) were further assigned to a treatment group (group A1, n = 130) receiving dexamethasone, 2 mg/kg/day by intravenous injection during the first 7 days of life, or to a control group (group A2, n = 118) receiving 10% dextrose solution placebo. Group B infants (prenatal betamethasone, n = 205) received neither treatment nor placebo. The incidence of NEC in group A1 was 6.9% (9/130), and in group A2 it was 14.4% (17/118) (p less than 0.05). In group B the incidence was 3.4% (7/205); this was much lower than in group A2 (p less than 0.01) and lower than in group A combined (10.4%) (p less than 0.01). There was no death from NEC and no surgical intervention among group B patients. The mortality rate for group A1 (11%) was lower than for group A2 (56%) (p less than 0.02). There were fewer indications for surgical intervention for NEC in group A1 than in group A2. Histologic studies confirmed bowel ischemia in all specimens analyzed. These data support the hypothesis that the incidence of NEC is significantly reduced after prenatal steroid treatment. Although postnatal therapy with steroids does not decrease the incidence as effectively as prenatal therapy, it improves clinical outcome of NEC.
Authors:
E Halac; J Halac; E F Bégué; J M Casañas; D R Indiveri; J F Petit; M J Figueroa; J M Olmas; L A Rodríguez; R J Obregón
Related Documents :
23591255 - Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive ...
23635805 - Plasma amyloid-β levels in drug-resistant bipolar depressed patients receiving electroc...
15241435 - Gene-environment interaction analysis of serotonin system markers with adolescent depre...
24839175 - Does cognitive-behavioural therapy promote meaning making? a preliminary test in the co...
12358325 - The italian multicentre study on noninvasive ventilation in chronic obstructive pulmona...
1755435 - From field experiments to program implementation: assessing the potential outcomes of a...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  117     ISSN:  0022-3476     ISO Abbreviation:  J. Pediatr.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-08-17     Completed Date:  1990-08-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  132-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Neonatology, Catholic University of Córdoba, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Betamethasone / administration & dosage,  therapeutic use*
Clinical Trials as Topic
Dexamethasone / administration & dosage,  therapeutic use*
Enterocolitis, Pseudomembranous / diagnosis,  prevention & control*
Female
Follow-Up Studies
Humans
Incidence
Infant, Newborn
Infant, Premature*
Injections, Intramuscular
Injections, Intravenous
Intensive Care, Neonatal
Male
Maternal-Fetal Exchange
Placebos
Pregnancy
Random Allocation
Risk Factors
Chemical
Reg. No./Substance:
0/Placebos; 378-44-9/Betamethasone; 50-02-2/Dexamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Frequent handling in the neonatal intensive care unit and intraventricular hemorrhage.
Next Document:  Growth hormone therapy for short stature: panacea or Pandora's box?